• Something wrong with this record ?

In vitro and in vivo anti-inflammatory active copper(II)-lawsone complexes

J. Vančo, Z. Trávníček, J. Hošek, P. Suchý,

. 2017 ; 12 (7) : e0181822. [pub] 20170725

Language English Country United States

Document type Journal Article

We report in vitro and in vivo anti-inflammatory activities of a series of copper(II)-lawsone complexes of the general composition [Cu(Law)2(LN)x(H2O)(2-x)]·yH2O; where HLaw = 2-hydroxy-1,4-naphthoquinone, x = 1 when LN = pyridine (1) and 2-aminopyridine (3) and x = 2 when LN = imidazole (2), 3-aminopyridine (4), 4-aminopyridine (5), 3-hydroxypyridine (6), and 3,5-dimethylpyrazole (7). The compounds were thoroughly characterized by physical techniques, including single crystal X-ray analysis of complex 2. Some of the complexes showed the ability to suppress significantly the activation of nuclear factor κB (NF-κB) both by lipopolysaccharide (LPS) and TNF-alpha (complexes 3-7 at 100 nM level) in the similar manner as the reference drug prednisone (at 1 μM level). On the other hand, all the complexes 1-7 decreased significantly the levels of the secreted TNF-alpha after the LPS activation of THP-1 cells, thus showing the anti-inflammatory potential via both NF-κB moderation and by other mechanisms, such as influence on TNF-alpha transcription and/or translation and/or secretion. In addition, a strong intracellular pro-oxidative effect of all the complexes has been found at 100 nM dose in vitro. The ability to suppress the inflammatory response, caused by the subcutaneous application of λ-carrageenan, has been determined by in vivo testing in hind-paw edema model on rats. The most active complexes 1-3 (applied in a dose corresponding to 40 μmol Cu/kg), diminished the formation of edema simalarly as the reference drug indomethacine (applied in 10 mg/kg dose). The overall effect of the complexes, dominantly 1-3, shows similarity to anti-inflammatory drug benoxaprofen, known to induce intracellular pro-oxidative effects.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030668
003      
CZ-PrNML
005      
20171025122718.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0181822 $2 doi
035    __
$a (PubMed)28742852
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vančo, Ján $u Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, 17. listopadu 12, Olomouc, Czech Republic.
245    10
$a In vitro and in vivo anti-inflammatory active copper(II)-lawsone complexes / $c J. Vančo, Z. Trávníček, J. Hošek, P. Suchý,
520    9_
$a We report in vitro and in vivo anti-inflammatory activities of a series of copper(II)-lawsone complexes of the general composition [Cu(Law)2(LN)x(H2O)(2-x)]·yH2O; where HLaw = 2-hydroxy-1,4-naphthoquinone, x = 1 when LN = pyridine (1) and 2-aminopyridine (3) and x = 2 when LN = imidazole (2), 3-aminopyridine (4), 4-aminopyridine (5), 3-hydroxypyridine (6), and 3,5-dimethylpyrazole (7). The compounds were thoroughly characterized by physical techniques, including single crystal X-ray analysis of complex 2. Some of the complexes showed the ability to suppress significantly the activation of nuclear factor κB (NF-κB) both by lipopolysaccharide (LPS) and TNF-alpha (complexes 3-7 at 100 nM level) in the similar manner as the reference drug prednisone (at 1 μM level). On the other hand, all the complexes 1-7 decreased significantly the levels of the secreted TNF-alpha after the LPS activation of THP-1 cells, thus showing the anti-inflammatory potential via both NF-κB moderation and by other mechanisms, such as influence on TNF-alpha transcription and/or translation and/or secretion. In addition, a strong intracellular pro-oxidative effect of all the complexes has been found at 100 nM dose in vitro. The ability to suppress the inflammatory response, caused by the subcutaneous application of λ-carrageenan, has been determined by in vivo testing in hind-paw edema model on rats. The most active complexes 1-3 (applied in a dose corresponding to 40 μmol Cu/kg), diminished the formation of edema simalarly as the reference drug indomethacine (applied in 10 mg/kg dose). The overall effect of the complexes, dominantly 1-3, shows similarity to anti-inflammatory drug benoxaprofen, known to induce intracellular pro-oxidative effects.
650    _2
$a zvířata $7 D000818
650    _2
$a antiflogistika $x terapeutické užití $7 D000893
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a měď $x chemie $x terapeutické užití $7 D003300
650    _2
$a krystalografie rentgenová $7 D018360
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a edém $x farmakoterapie $7 D004487
650    _2
$a lidé $7 D006801
650    _2
$a zánět $x farmakoterapie $7 D007249
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a NF-kappa B $x antagonisté a inhibitory $7 D016328
650    _2
$a naftochinony $x chemie $x terapeutické užití $7 D009285
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a hmotnostní spektrometrie s elektrosprejovou ionizací $7 D021241
655    _2
$a časopisecké články $7 D016428
700    1_
$a Trávníček, Zdeněk $u Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, 17. listopadu 12, Olomouc, Czech Republic.
700    1_
$a Hošek, Jan $u Department of Inorganic Chemistry & Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, 17. listopadu 12, Olomouc, Czech Republic.
700    1_
$a Suchý, Pavel $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackého tř. 1946/1, Brno, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 12, č. 7 (2017), s. e0181822
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28742852 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025122800 $b ABA008
999    __
$a ok $b bmc $g 1254261 $s 991695
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c 7 $d e0181822 $e 20170725 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...